Venetoclax is being codeveloped by AbbVie and Genentech, a member of the Roche Group, and Onyx Therapeutics, Inc., a wholly owned subsidiary of Amgen Inc.

PART 1 (n=9-18)

- Cohort 1
  - Ven: 400 mg
  - Car: (20) 27 mg/m²
  - Dex: 40 mg

- Cohort 2
  - Ven: 800 mg
  - Car: (20) 27 mg/m²
  - Dex: 40 mg

- Cohort 3
  - Ven: 800 mg
  - Car: (20) 70 mg/m²
  - Dex: 40 mg

- Cohort 4*
  - Ven: RP2D
  - Car: RP2D
  - Dex: RP2D

PART 2 (n=22-31)

- Ven: RP2D
- Car: RP2D
- Dex: RP2D

Key Inclusion Criteria

- ECOG performance score ≤ 2
- Relapsed or refractory multiple myeloma
- 1 to 3 prior lines of therapy
- Carfilzomib naive

Key Endpoints

Primary
- Safety and tolerability

Secondary*
- Response rates (ORR, VGPR or better)
- Progression-free survival
- Pharmacokinetics
- Efficacy in high BCL-2 expression
- Minimal residual disease (MRD) in the bone marrow by next generation sequencing (NGS)

Exploratory
- Predictive biomarkers
- Patient reported outcomes

Venetoclax is being investigated for indications that have not been approved by Regulatory Agencies. Safety and Efficacy have not been established in unapproved indications.

* Cohort 4 to be investigated for exploratory purposes if deemed appropriate.

**To learn more about these studies, please visit https://ClinicalTrials.gov or email abbvieclinicaltrials@abbvie.com